背景一般认为,干扰血管的胶原部位阻滞Gp VI-依赖径路是心肌梗死或脑卒中等急性动脉粥样硬化性疾病的一个具有吸引力的抗血小板治疗目标。临床前研究曾反映,Revacept(可溶性dimeric GpⅥ-Fc fusion protein)通过阻断斑块或糜烂血管胶原,减少血小板黏附,应用安全。作者报告一项剂量递升的I期临床研究,旨在评估Revacept应用于人体的安全性、耐受 Background It is generally accepted that Gp VI-dependent pathways that disrupt vascular collagen-site arrest are an attractive antiplatelet therapy target for acute atherosclerotic diseases such as myocardial infarction or stroke. Preclinical studies have shown that Revacept (soluble dimeric GpVI-Fc fusion protein) can be used safely by blocking plaque or debilitating vascular collagen and reducing platelet adhesion. The authors report a phase I clinical trial of dose escalation to assess the safety and tolerability of Revacept in the human body